Clinical trials: Survivorship
Hepatocellular Carcinoma
Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)
To evaluate Quality of Life (QoL) score of MS-20 versus placebo in advanced HCC patients using European Organization for Research and Treatment of Cancer (EORTC) QLQ C-30 questionnaire.
- Trial name
- NCT00707681
- Testing
- MS-20
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Microbio Co Ltd
Epithelial Ovarian Cancer
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.
The OReO study will be a Phase IIIb, randomised, double-blind, placebo-controlled, multicentre study to assess the efficacy and tolerability of Olaparib retreatment, versus matching placebo, in non-mucinous epithelial ovarian…
- Trial name
- OReO (NCT03106987)
- Testing
- Active Comparator: Olaparib tablets
- Where
- 82 sites in Belgium, Canada and 9 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
Kidney Transplantation in Highly Sensitized Patients
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to…
- Trial name
- ConfIdeSLTFU (NCT05714514)
- Testing
- Imlifidase administered in the ConfIdeS study, Best available treatment administered in the ConfIdeS study
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Hansa Biopharma AB
Diffuse Large B-cell Lymphoma
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00474188
- Testing
- CC-5013 (lenalidomide), dexamethasone
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Celgene Corporation
Endocrine Tumors
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
- Trial name
- CLARINET (NCT00353496)
- Testing
- lanreotide (Autogel formulation)
- Where
- 71 sites in United States, Austria and 13 more
- Volunteers
- 264 people
- Sponsor
- Ipsen
Healthy
Recovery and Survival of EryDex in Non-patient Volunteers
This is a randomized, single-blind, single-center, concurrently controlled, exploratory, Phase I study to determine the in vivo kinetics (24-hour post-infusion recovery and T50 survival) of EryDex System (EDS) -processed…
- Trial name
- NCT02380924
- Testing
- DSP loaded RBC using EryDex System
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Quince Therapeutics S.p.A.
Healthy
Survival of the Probiotic Lacticaseibacillus Paracasei Strain Shirota (LcS) in the GI Tract of Healthy Adults
The objective of this study is to investigate the survival of Lacticaseibacillus paracasei strain Shirota (LcS) in the human gastrointestinal (GI) tract after consumption of probiotics fermented milk product containing 8x10^9…
- Trial name
- NCT05522777
- Testing
- Drink one bottle of Yakult a day
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Yakult U.S.A. Inc.
Lymphocytic Leukemia, Chronic
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
This study will assess the effect of maintenance treatment with rituximab in comparison with observation period (no treatment), in participants with progressive B-cell CLL who have had previous first-line induction treatment with…
- Trial name
- NCT00718549
- Testing
- Cladribine, Cyclophosphamide, Rituximab
- Where
- 6 sites in Belarus, Poland
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Recurrent Platinum-sensitive Ovarian Cancer
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.
- Trial name
- NCT01837251
- Testing
- Carboplatin, PLD, Bevacizumab
- Where
- 193 sites in Australia, Austria and 4 more
- Volunteers
- 682 people
- Sponsor
- AGO Research GmbH
Melanoma
CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy
The trial is designed as a phase II evaluation of the effect of CY-503 on progression free survival (PFS) in patients with stage IV malignant melanoma after failure of prior therapy.
- Trial name
- NCT00658437
- Testing
- CY-503
- Where
- 4 sites in Germany
- Volunteers
- 31 people
- Sponsor
- Cytavis Biopharma GmbH
NSCLC
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2.
- Trial name
- PIONEER (NCT00269828)
- Testing
- paclitaxel, paclitaxel poliglumex
- Where
- 143 sites in United States, Argentina and 9 more
- Volunteers
- 600 people
- Sponsor
- CTI BioPharma
Diffuse Large B-cell Lymphoma
Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.
This was a retrospective non-interventional cohort study design using the Centers for Medicare and Medicaid Services (CMS) 100% Medicare data (2015Q1-2020Q4).
- Trial name
- NCT06271369
- Where
- United States
- Volunteers
- 613 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma Multiforme
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
- Trial name
- NCT02586857
- Testing
- ACP-196
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acerta Pharma BV
Breast Cancer
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
This randomized study will compare maintenance therapy with Avastin (bevacizumab) + Xeloda (capecitabine) versus Avastin alone, in patients with HER2-negative metastatic breast cancer who have not progressed during first-line…
- Trial name
- NCT00929240
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda]
- Where
- 63 sites in Brazil, China and 9 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis
Regarding Tofacitinib, newly introduced on the market, few data on drug retention and no data on the factors predictive of Tofacitinib drug survival in patients with RA are available.
- Trial name
- NCT03981900
- Testing
- Tofacitinib
- Where
- 66 sites in France
- Volunteers
- 314 people
- Sponsor
- Pfizer
Ovarian Cancer
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with…
- Trial name
- NCT00976911
- Testing
- Bevacizumab, liposomal doxorubicin, paclitaxel
- Where
- 117 sites in Belgium, Bosnia and Herzegovina and 12 more
- Volunteers
- 361 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer NSCLC
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC…
- Trial name
- POSEIDON (NCT03164616)
- Testing
- Durvalumab, Tremelimumab, Abraxane + carboplatin
- Where
- 175 sites in United States, Brazil and 17 more
- Volunteers
- 1,186 people
- Sponsor
- AstraZeneca
Osteoarthritis, Hip, Arthritis
Longterm-Evaluation of Vitelene® Against Standard
The purpose of this randomised prospective multicenter longterm study is to evaluate the survival rate of the implant, wear and periprosthetic osteolysis of highly cross-linked polyethylene with and without addition of Vitamin E…
- Trial name
- VITAS (NCT01713062)
- Testing
- Vitelene, XLPE
- Where
- 6 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Aesculap AG
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
In this study, participants with programmed cell death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) will be randomized to receive single agent pembrolizumab for up to 35 treatments or standard of care (SOC)…
- Trial name
- NCT02220894
- Testing
- pembrolizumab, carboplatin, paclitaxel
- Volunteers
- 1,274 people
- Sponsor
- Merck Sharp & Dohme LLC